Fiduciary Group LLC lessened its stake in shares of Becton Dickinson and Co (NYSE:BDX) by 9.2% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 15,389 shares of the medical instruments supplier’s stock after selling 1,554 shares during the quarter. Fiduciary Group LLC’s holdings in Becton Dickinson and were worth $4,017,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors also recently bought and sold shares of BDX. LPL Financial LLC increased its position in Becton Dickinson and by 44.6% during the 1st quarter. LPL Financial LLC now owns 38,315 shares of the medical instruments supplier’s stock worth $8,303,000 after purchasing an additional 11,812 shares in the last quarter. Royal Bank of Canada grew its holdings in Becton Dickinson and by 20.0% in the 1st quarter. Royal Bank of Canada now owns 545,866 shares of the medical instruments supplier’s stock valued at $118,289,000 after buying an additional 91,016 shares during the period. Xact Kapitalforvaltning AB grew its holdings in Becton Dickinson and by 23.7% in the 1st quarter. Xact Kapitalforvaltning AB now owns 46,114 shares of the medical instruments supplier’s stock valued at $9,993,000 after buying an additional 8,829 shares during the period. Moors & Cabot Inc. grew its holdings in Becton Dickinson and by 4.0% in the 1st quarter. Moors & Cabot Inc. now owns 8,792 shares of the medical instruments supplier’s stock valued at $1,905,000 after buying an additional 340 shares during the period. Finally, CIBC World Markets Inc. grew its holdings in Becton Dickinson and by 54.5% in the 1st quarter. CIBC World Markets Inc. now owns 30,059 shares of the medical instruments supplier’s stock valued at $6,514,000 after buying an additional 10,609 shares during the period. Hedge funds and other institutional investors own 92.51% of the company’s stock.
Several analysts have commented on BDX shares. ValuEngine upgraded Becton Dickinson and from a “hold” rating to a “buy” rating in a report on Tuesday, June 26th. Morgan Stanley lifted their price target on Becton Dickinson and from $250.00 to $280.00 and gave the company an “equal weight” rating in a report on Thursday, October 4th. KeyCorp restated a “buy” rating and issued a $264.00 price target on shares of Becton Dickinson and in a report on Friday, August 3rd. JPMorgan Chase & Co. upgraded Becton Dickinson and from a “neutral” rating to an “overweight” rating and set a $175.00 price target for the company in a report on Thursday, June 21st. Finally, Citigroup lifted their price target on Becton Dickinson and from $274.00 to $283.00 and gave the company a “buy” rating in a report on Wednesday, August 8th. Five research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $255.40.
Shares of NYSE BDX traded down $3.99 during midday trading on Thursday, hitting $240.99. The stock had a trading volume of 30,242 shares, compared to its average volume of 1,160,385. The firm has a market capitalization of $69.83 billion, a P/E ratio of 25.47, a P/E/G ratio of 1.78 and a beta of 1.11. Becton Dickinson and Co has a 1-year low of $202.73 and a 1-year high of $265.87. The company has a debt-to-equity ratio of 0.95, a current ratio of 1.23 and a quick ratio of 0.81.
Becton Dickinson and (NYSE:BDX) last released its quarterly earnings data on Thursday, August 2nd. The medical instruments supplier reported $2.91 earnings per share for the quarter, beating the consensus estimate of $2.86 by $0.05. The business had revenue of $4.28 billion for the quarter, compared to analyst estimates of $4.25 billion. Becton Dickinson and had a return on equity of 14.16% and a net margin of 4.73%. The company’s revenue was up 41.0% compared to the same quarter last year. During the same period in the previous year, the company posted $2.46 EPS. On average, equities research analysts expect that Becton Dickinson and Co will post 11.01 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which was paid on Friday, September 28th. Stockholders of record on Friday, September 7th were paid a $0.75 dividend. This represents a $3.00 annualized dividend and a dividend yield of 1.24%. The ex-dividend date of this dividend was Thursday, September 6th. Becton Dickinson and’s dividend payout ratio is currently 31.65%.
Becton Dickinson and Company Profile
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and other products for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laparoscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; medication inventory optimization and tracking systems; and prefillable drug delivery systems.
Featured Story: What is the float in trading stocks?
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.